Alejandro
Martín García Sancho
![Foto de Alejandro](/img/uploaded/7995d893f771731596c395e1ae877d0d.jpg)
![Foto de University of Texas MD Anderson Cancer Center](/img/noimage_org.png)
University of Texas MD Anderson Cancer Center
Houston, Estados UnidosPublicacions en col·laboració amb investigadors/es de University of Texas MD Anderson Cancer Center (5)
2023
-
Phase 3 SELENE study: ibrutinib plus BR/R-CHOP in previously treated patients with follicular or marginal zone lymphoma
Blood Advances, Vol. 7, Núm. 22, pp. 7141-7150
-
ROSEWOOD: A Phase II Randomized Study of Zanubrutinib Plus Obinutuzumab Versus Obinutuzumab Monotherapy in Patients with Relapsed or Refractory Follicular Lymphoma
Journal of Clinical Oncology
2022
2020
-
New prognosis score including absolute lymphocyte/monocyte ratio, red blood cell distribution width and beta-2 microglobulin in patients with diffuse large B-cell lymphoma treated with R-CHOP: Spanish Lymphoma Group Experience (GELTAMO)
British Journal of Haematology, Vol. 188, Núm. 6, pp. 888-897
2018
-
Rituximab plus lenalidomide in advanced untreated follicular lymphoma
New England Journal of Medicine, Vol. 379, Núm. 10, pp. 934-946